Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

“…Two factors, time of disease control greater than 6 months and lack of metastases at presentation, have already been identified as prognostic factors of overall survival in the Thiery-Vuillemin et al study [28]. Indeed, improving overall survival could increase the duration of treatment and therefore the cost-of-illness.…”

“…However, targeted therapies for mccRCC have brought both new hope and new challenges, considerably expanding the number of treatment options for this indication. Because we have come to question the clinical and economic impact of systematically/routinely using these targeted therapies for patients with mccRCC, we decided to assess their effectiveness and cost-of-illness [28]. Thus, all patients with mccRCC treated over an eight-year period in three main oncology treatment centers of our Franche-Comté region were included in this retrospective study.…”

“…From January 2007 to March 2015, all consecutive patients with histologically confirmed mccRCC who started their first-line treatment with a targeted therapy in 3 main oncology treatment sites of the Institut Régional Fédératif du Cancer de Franche-Comté were included in the analysis The selection procedure of 224 patients with histologically confirmed mccRCC who started their first-line treatment with a targeted therapy was previously presented by Thiery-Vuillemin et al [28]. Each anticancer drug was given until disease progression, toxicity or death and was routinely administered according to 5 guidelines and the summary of product characteristics.…”

“…On the other hand, clinical and economic studies in daily practice are sparse [18][19][20][21][22][23][24][25][26][27]. A previous retrospective multicenter study was conducted to assess the effectiveness of targeted therapies in real life settings [28]. All patients with histologically confirmed mccRCC who received targeted therapies in first-line treatment were included.…”

“…However, despite the importance of mccRCC, data concerning its economic burden are few. Thus, the purpose of this retrospective study was to evaluate the cost-of-illness for 224 patients with diagnosed mccRCC included in the cohort published by Thiery-Vuillemin et al, and then to determine the explanatory factors of costof-illness [28].…”